Copyright
©The Author(s) 2022.
World J Psychiatry. Mar 19, 2022; 12(3): 410-424
Published online Mar 19, 2022. doi: 10.5498/wjp.v12.i3.410
Published online Mar 19, 2022. doi: 10.5498/wjp.v12.i3.410
Figure 8 Magnesium-L-threonate treatment activated the phosphatidylinositol-3-kinase/protein kinase B pathway in APPswe/PS1dE9 mouse hippocampus.
A: Protein band images of phosphorylated (p)-phosphatidylinositol-3-kinase (PI3K), PI3K, p-protein kinase B (Akt), Akt and glyceraldehyde-3-phosphate dehydrogenase of each group; B: The p-PI3K/PI3K ratio of each group; C: The p-Akt/Akt ratio of each group. n = 3. aP < 0.05, bP < 0.01, cP < 0.001 vs former group. MgT: Magnesium-L-threonate; PI3K: phosphatidylinositol-3-kinase; Akt: protein kinase B; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; WT: Wild-type mice group; TG: APPswe/PS1dE9 mice group.
- Citation: Xiong Y, Ruan YT, Zhao J, Yang YW, Chen LP, Mai YR, Yu Q, Cao ZY, Liu FF, Liao W, Liu J. Magnesium-L-threonate exhibited a neuroprotective effect against oxidative stress damage in HT22 cells and Alzheimer’s disease mouse model. World J Psychiatry 2022; 12(3): 410-424
- URL: https://www.wjgnet.com/2220-3206/full/v12/i3/410.htm
- DOI: https://dx.doi.org/10.5498/wjp.v12.i3.410